



Supplemental Figure 1 – Dose-response curves of each Hsp90i in FF cells are shown with corresponding 24 hrs IC₅₀ values tabulated in micromolar concentrations.




	IC ₅₀ (μM)
XL888	113.3
KU758	4.05
WGA-TA	2.28

Supplemental Figure 2 – The combination effect of Hsp90 inhibitor combinations in UACC-62. Ve+Cb combination (FDA approved) is shown for comparison.



Supplemental Figure 3 - Dose-response curves of Hsp90i KU758 in melanoma cells are shown with corresponding 24 hrs IC₅₀ values tabulated in micromolar concentrations.



Supplemental Table 1 – The CI values are listed for each inhibitor combination treatment in UACC-62 between (A) Hsp90i and MAPKi, as well as (B) Ve+Cb. Synergistic combination boxes are colored according to relative CI value: CI value < 0.5 (blue), 0.5 < CI value < 1.0 (green).

A)

		KU758			WGA-TA			XL888			
		(μ M)	0.125	0.25	0.5	0.025	0.5	0.1	0.075	0.15	0.3
Ve	12.5	1.445	0.428	0.291	116.814	0.353	0.070	8.166	7.199	2.580	
	25	1.452	0.340	0.262	1.636	0.181	0.045	5.645	2.136	1.732	
	50	0.815	0.248	0.185	0.231	0.074	0.037	0.725	0.536	0.757	
Cb	0.125	1.166	0.735	0.315	1.198	1.557	1.701	0.895	0.236	0.342	
	0.25	1.014	0.717	0.235	0.994	1.341	1.514	0.362	0.282	0.410	
	0.5	0.723	0.883	0.202	0.887	1.063	1.326	0.522	0.364	0.471	

B)

		Cb			
		(μ M)	0.125	0.25	0.5
Ve	12.5	0.447	0.460	0.757	
	25	0.086	0.152	0.272	
	50	0.048	0.098	0.188	

Supplemental Figure 4 – Scratch and Boyden chamber assays in UACC-62. A) KU758 inhibitor combinations decreased cell migration (red lines indicate scratched cell-free area). B) quantification of the percent of cell migration at 24 hours after Hsp90i and MAPKi combinations. p values are recorded as significance between t = 0 and 24 hrs. C) The number of migrated cells after inhibitor single-agent and combination treatments.

